Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1196 results
July 2015
-
Media ReleaseNovartis delivered solid performance in the second quarter, with strong innovation and progress on new launchesSales, core[1] operating income and core EPS grew (cc[1]) for continuing operations[2] in Q2: Net sales amounted to USD 12.7 billion (-5%, +6% cc) Operating income was USD 2.3…
-
Media ReleaseNovartis: solide performance au deuxième trimestre grâce à la force de l'innovation et aux progrès des nouveaux lancementsCroissance des ventes, du résultat opérationnel core[1] et du BPA core (tcc[1]) des activités poursuivies[2] au T2: Le chiffre d'affaires net s'est élevé à USD 12,7 milliards (-5%, +6% tcc). Le…
-
Media ReleaseNovartis erzielt im zweiten Quartal eine solide Performance mit starken Innovationen und Fortschritten bei NeueinführungenDie fortzuführenden Geschäftsbereiche[2] steigern im zweiten Quartal den Umsatz, das operative Kernergebnis[1] und den Kerngewinn pro Aktie (kWk[1]): Der Nettoumsatz beläuft sich auf USD 12,7…
-
Media ReleaseNovartis malaria treatment Coartem® 80/480mg receives WHO prequalification, enabling greater access for patientsWHO prequalified Coartem® 80/480mg is the first and only high strength malaria treatment available for donor-funded public sector procurement Coartem® 80/480mg reduces the pill burden for…
-
Media ReleaseNovartis' new heart failure medicine LCZ696, now called Entresto(TM), approved by FDA to reduce risk of cardiovascular death and heart failure hospitalizationFirst in the world approval brings hope of longer life and fewer hospitalizations for millions of Americans with heart failure with reduced ejection fraction Entresto is the first and only treatment…
-
Media ReleaseAlcon receives European Approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surgeryAcrySof® IQ Aspheric Intraocular Lens (IOL) with UltraSertTM Pre-loaded Delivery System helps to maintain the integrity of the incision while facilitating smooth, consistent delivery of the IOL…
June 2015
-
Media ReleaseNovartis Pharmaceuticals launches the first app for visually impaired people for use with the Apple Watch and other smart watchesNew features of the ViaOpta apps, previously available for iPhone and AndroidTM mobile phones, are also available to enhance the daily lives of people with visual impairments These apps…
-
Media ReleaseNovartis deepens its industry leading pipeline with acquisition of Spinifex Pharmaceuticals, Inc.Acquisition adds novel angiotensin II Type 2 receptor antagonist for the treatment of neuropathic pain to Novartis' industry-leading development pipeline Neuropathic pain is a chronic…
-
Media ReleaseNovartis announces publication in The Lancet showing sustained efficacy with secukinumab over one year in psoriatic arthritis patientsIn the FUTURE 2 study, secukinumab demonstrated rapid onset of action, was significantly superior to placebo in improving signs and symptoms of psoriatic arthritis (PsA), with efficacy sustained…
-
Media ReleaseNovartis drug Farydak® recommended by CHMP for EU approval to treat multiple myeloma, providing patients a new mechanism of actionFarydak (panobinostat) combination improved PFS by 7.8 months for patients who received >=2 prior regimens including bortezomib and an IMiD[1] Farydak would be the first HDAC inhibitor with…
-
Media ReleaseSandoz announces US launch of Glatopa(TM), the first generic competitor to Copaxone® 20mgGlatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis Sandoz has begun shipping to US customers…
-
Media ReleaseNovartis highlights strong innovation momentum at its second Meet Novartis Management investor dayStrong progress on innovation across divisions Pharmaceuticals is building breadth and depth in seven franchises, including Oncology, where it is complementing leadership in targeted therapies and…
Pagination
- ‹ Previous page
- 1
- …
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- …
- 100
- › Next page